1035573-34-2

Upstream product

• 1035572-31-6 {6-[2-(3,5-dichloropyridin-4-yl)acetyl]-2,3-dimethoxyphenoxy}aceticacid 
• 6395-18-2 methyl 2,3,4-trimethoxybenzoate 
• 100868-46-0 3,5-dichloro-4-picoline 
• 1035571-47-1 {6-[2-(3,5-dichloropyridin-4-yl)-acetyl]-2,3-dimethoxyphenoxy}acetic acid ethyl ester 
• 1035571-27-7 2-(3,5-dichloro-4-pyridinyl)-1-(2-hydroxy-3,4-dimethoxyphenyl)ethanone 
• 208043-54-3 [2-(3,5-Dichloro-pyridin-4-yl)-1-oxoethyl]-2,3,4-trimethoxybenzene 
• 1035572-33-8 N-benzyl-2-{6-[2-(3,5-dichloropyridin-4-yl)acetyl]-2,3-dimethoxyphenoxy}acetamide 

Relevant academic research and scientific papers

Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4- pyridyl)acetyl]-2,3-dimethoxyphenoxy}- N -propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis

Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades. However, only roflumilast has received FDA approval. One key challenge has been the low therapeutic window observed in the clin

SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS

The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent -CH- or N; or X3, X4 and X5